The inhibition of the transplacental blastomogenic effect of nitrosomethylurea by postnatal administration of buformin to rats

Alexandrov, V. A.; Anisimov, Vladimir N.; Belous, Natalia M.; Vasilyeva, Inna A.; Mazon, Vera B.

doi:10.1093/carcin/1.12.975

Cited by 27 publications

(16 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A decrease of glucose utilization in the oral glucose tolerance test was found in the 3-month-old female progeny of rats exposed to NMU on the 21 st day of pregnancy [201]. The serum insulin level was not different from the control, but the cholesterol level was higher in offspring of NMU-treated rats as compared with the control.…”

Section: Pharmacological Modulation Of Gh/insulin/igf-1 Signaling mentioning

confidence: 99%

The key role of growth hormone–insulin–IGF-1 signaling in aging and cancer

Anisimov

Bartke

2013

Critical Reviews in Oncology/Hematology

Self Cite

183

123

View full text Add to dashboard Cite

Studies in mammals have led to the suggestion that hyperglycemia and hyperinsulinemia are important factors in aging. GH/Insulin/insulin-like growth factor 1 (IGF-1) signaling molecules that have been linked to longevity include daf-2 and InR and their homologues in mammals, and inactivation of the corresponding genes increases lifespan in nematodes, fruit flies and mice. The life-prolonging effects of caloric restriction are likely related to decreasing IGF-1 levels. Evidence has emerged that antidiabetic drugs are promising candidates for both lifespan extension and prevention of cancer. Thus, antidiabetic drugs postpone spontaneous carcinogenesis in mice and rats, as well as chemical and radiation carcinogenesis in mice, rats and hamsters. Furthermore, metformin seems to decrease the risk for cancer in diabetic patients.

show abstract

Section: Pharmacological Modulation Of Gh/insulin/igf-1 Signaling mentioning

confidence: 99%

The key role of growth hormone–insulin–IGF-1 signaling in aging and cancer

Anisimov

Bartke

2013

Critical Reviews in Oncology/Hematology

Self Cite

183

123

View full text Add to dashboard Cite

show abstract

“…Antidiabetic biguanides have been proposed for the prevention of the age-related increases of cancer and atherosclerosis and for the retardation of the aging processes [12,21]. It was shown that administration of phenformin lowers blood cholesterol, triglyceride, and ß-lipoprotein levels in patients with hyperlipidemia, inhibits the development of atherosclerosis, reduces hyperinsulinemia in men with coronary artery disease, increases hypothalamopituitary sensitivity to inhibition by dexamethasone, causes restoration of the estrous cycle in persistent-estrous old rats, improves cellular immunity in atherosclerotic and cancer patients, lowers blood somatomedin-like levels in cancer and atherosclerotic patients with type IIb hyperlipoproteinemia, inhibits mammary, colon, and transplacental carcinogenesis in rats, and prolongs the life span of mice and rats [12,22,[46][47][48][49][50][51]. It is worth noting that mutations in Caenorhabditis elegans that reduce overall insulin signaling decrease accumulation of oxidized proteins, increase MnSOD activity, decrease oxidative stress, and extend the life span [51][52][53][54].…”

Section: Antidiabetic Treatmentmentioning

confidence: 99%

Effects of Phentermine and Phenformin on Biomarkers of Aging in Rats

et al. 2004

Self Cite

View full text Add to dashboard Cite

Background: Caloric restriction (CR) is the only treatment known to substantially prolong both average and maximal life span in experimental animals. Interventions that mimic certain effects of CR could be potential anti-aging treatments in humans. Drugs which reduce appetite (anorexiants) represent one class of candidate treatments. Agents that reduce the glucose utilization by the organism could also represent another class of candidate CR mimetics. Objective: In our study, we addressed the following questions: (1) Does treatment with an anorexiant reduce caloric intake and body weight of experimental animals comparable to that caused by CR? (2) Does treatment with an antidiabetic agent influence caloric intake and body weight? (3) Does treatment with any of these drugs affect metabolic parameters of an organism in the way similar to that observed with CR? Methods: One hundred and twenty 6-month-old female Wistar-derived LIO rats were randomly subdivided into four groups and exposed to: (1) ad libitum feeding with placebo (controls); (2) the antidiabetic drug phenformin (2 mg/kg); (3) the anorectic drug phentermine (1 mg/kg), and (4) the same amount of food as the group with the least food intake during the previous week (pair-fed controls). Food and water intake, body weight, and rectal temperature were measured weekly during 16 weeks. At the end of the 16th week of the experiment, serum levels of glucose, total β-lipoprotein and pre-β-lipoprotein fractions, cholesterol, triglycerides, insulin, total triiodothyronine, and free thyroxine were estimated. The contents of diene conjugates and Schiff’s bases, total antioxidant activity, the activities of Cu/Zn superoxide dismutase, glutathione S-transferase, and glutathione peroxidase, and the generation of reactive oxygen species (ROS) were studied in brain and liver homogenates and in the serum. Results: The controls exposed to pair feeding had a significantly reduced food consumption (about 20%) as compared with the ad libitum fed controls and thus exhibited a moderate CR. Treatment with phentermine reduced the caloric intake by about 12% as compared with the ad libitum fed controls. Body weight and water intake in this group were only slightly decreased (by about 2 and 5%, respectively) as compared with the controls. The mean rectal temperature in the phentermine group (38°C) was significantly higher than in the ad libitum fed (37.8°C) and pair-fed (37.6°C) controls. Treatment with phentermine also resulted in significantly reduced ROS levels in all tissues studied, while the highest ROS production was found in ad libitum (blood serum) and pair-fed (brain) controls. Treatment with phenformin did not significantly influence food and water consumption, body weight, and temperature when compared with the ad libitum fed controls. Rats treated with this antidiabetic drug showed intermediate values of ROS generation. Differences among the groups in total antioxidant activity were not obvious. Conclusions: Treatment with phentermine reduces caloric intake slightly le...

show abstract

“…A decrease of glucose utilisation in the oral glucose tolerance test was found in the 3-month-old female progeny of rats exposed to NMU on the 21st day of pregnancy [115]. The serum insulin level was not differ from the control, but the cholesterol level was higher in offspring of NMU-treated rats as compared with the control.…”

Section: Introductionmentioning

confidence: 99%

Metformin for aging and cancer prevention

Anisimov

2010

Aging

Self Cite

133

102

View full text Add to dashboard Cite

Studies in mammals have led to the suggestion that hyperglycemia and hyperinsulinemia are important factors in aging. Insulin/insulin-like growth factor 1 (IGF-1) signaling molecules that have been linked to longevity include daf-2 and InR and their homologues in mammals, and inactivation of the corresponding genes increases life span in nematodes, fruit flies and mice. It is possible that the life-prolonging effect of caloric restriction is due to decreasing IGF-1 levels. Evidence has emerged that antidiabetic drugs are promising candidates for both life span extension and prevention of cancer. Thus, antidiabetic drugs postpone spontaneous carcinogenesis in mice and rats, as well as chemical and radiation carcinogenesis in mice, rats and hamsters. Furthermore metformin seems to decrease cancer risk in diabetic patients.

show abstract

The inhibition of the transplacental blastomogenic effect of nitrosomethylurea by postnatal administration of buformin to rats

Cited by 27 publications

References 0 publications

The key role of growth hormone–insulin–IGF-1 signaling in aging and cancer

The key role of growth hormone–insulin–IGF-1 signaling in aging and cancer

Effects of Phentermine and Phenformin on Biomarkers of Aging in Rats

Metformin for aging and cancer prevention

Contact Info

Product

Resources

About